comparemela.com


Will antibody cocktail of Roche reduce demand for Tocilizumab: Delhi High Court
SECTIONS
Last Updated: May 14, 2021, 01:02 PM IST
Share
Synopsis
The query was posed to the government by Justice Prathiba M Singh after Roche India, which supplies Tocilizumab in India, told the court it can only endeavour to supply the medicine and cannot assure to meet the market demand for the same, even though patients are willing to pay for it.
Getty Images
The court noted that the global manufacturing figures of the drug have not been filed before it by Roche despite specific directions.
The Delhi High Court has asked the Centre whether demand for COVID-19 drug Tocilizumab, which is in short supply, would be reduced if drug major Roche provides its new antibody cocktail that has been approved for emergency use in India for coronavirus patients. The court also asked the Centre what quantities of the antibody cocktail would be required for the purpose of reducing demand for Tocilizumab.

Related Keywords

Japan ,Delhi ,India ,Switzerland ,Archana Sahadeva ,Anurag Ahluwalia ,Justice Prathibam Singh ,Chugai Seiyaku Kabushki Kaisha ,Roche Ltd ,Research India Pvt ,Cipla ,Hetero Biopharma Ltd ,Delhi High Court ,Roche India ,Biopharma Ltd ,Research India ,Clinical Guidelines ,Tocilizumab ,Centre ,Antibody Cocktail ,Adults ,Icmr ,ஜப்பான் ,டெல்ஹி ,இந்தியா ,சுவிட்சர்லாந்து ,அர்ச்சனா சஹாதேவா ,ரோச் லிமிடெட் ,சிப்லா ,டெல்ஹி உயர் நீதிமன்றம் ,ரோச் இந்தியா ,ஆராய்ச்சி இந்தியா ,மருத்துவ வழிகாட்டுதல்கள் ,மையம் ,ஆன்டிபாடி காக்டெய்ல் ,இக்மிர் ,

© 2025 Vimarsana

comparemela.com © 2020. All Rights Reserved.